Anti-Human CA9 Recombinant Antibody (MSC3) (CAT#: TAB-1458CL)

Figure 1 Binding specificity of the purified constructs.

Flow cytometric analysis of Fab MSC 3 on human (A) or murine (B) cell lines induced for 48 h in 0.2% 02 (grey) or normoxia (white).

Figure 2 Carbonic anhydrase activity, normalized to a scale where activity measured in HCTl 16-CAIX and HCTl 16-EV membrane fragments are one and zero, respectively.

Asterisks denote significant reduction in activity (MSC5, MSC 10„MSC12 and MSC8 Fab antibodies).

Figure 1 Anti-Human CA9 Recombinant Antibody (TAB-1458CL) in SDS-PAGE

SDS-PAGE analysis of TAB-1458CL in non-reduced (Lane 1) and β-mercaptoethanol-reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.

Figure 2 Anti-Human CA9 Recombinant Antibody (TAB-1458CL) in SEC-HPLC

The purity of TAB-1458CL was 97.3361% as determined by SEC-HPLC

Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl

Figure 3 Anti-Human CA9 Recombinant Antibody (TAB-1458CL) in ELISA

ELISA analysis of TAB-1458CL was performed by coating with Recombinant Human Carbonic Anhydrase IX protein (His tag).
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 4 Anti-Human CA9 Recombinant Antibody (TAB-1458CL) in WB

Western blot analysis of TAB-1458CL was performed by loading Recombinant Human Carbonic Anhydrase IX protein (His tag).

TAB-1458CL incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Lane 1: Reduced antigen (0.1 μg)
Lane 2: Reduced antigen (0.3 μg)
Lane 3: Reduced antigen (0.6 μg)

Figure 5 Anti-Human CA9 Recombinant Antibody (TAB-1458CL) in DB

Dot blot analysis of TAB-1458CL was performed by loading Recombinant Human Carbonic Anhydrase IX protein (His tag).

TAB-1458CL incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)